1. Home
  2. Clinical Topics
  3. FDA approves single REMS for transmucosal immediate-release fentanyl products
Clinical TopicsDrugs and DevicesNewsPatient SafetyWeb ExclusivesWorkplace Management

FDA approves single REMS for transmucosal immediate-release fentanyl products

Share

The U.S. Food and Drug Administration has approved a single shared Risk Evaluation and Mitigation Strategy (REMS) for transmucosal immediate-release fentanyl (TIRF) products. This new system will replace individual REMS and allow prescribers to enroll into just one system. Read more.

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts